Kornimate/medical-research-clean huggingface dataset:
physical activity in people with sequelae of poliomyelitis

Conditions: Poliomyelitis

Summary: people with disabilities are less physically active than the general population. at present, the physical activity level of people with poliomyelitis sequelae and their barriers to physical activity are unknown. the aim of this study is to describe the physical activity level of people with poliomyelitis sequelae and their barriers to physical activity.

this is a cross-sectional, monocentric, cohort study of subjects with poliomyelitis sequelae followed in a physical medicine and rehabilitation department. all consecutive eligible outpatient subjects consulting to the physical medicine and rehabilitation department of our university hospital will be included. data will be collected from the patients' medical records, in particular data related to their clinical, radiological, biological and physiological examinations. it is an ancillary study to the no-aging study.

Eligibility criteria:
inclusion criteria: * consulting to the physical medicine and rehabilitation department of our university hospital * having poliomyelitis sequelae * no opposition to be enrolled in the study from the patient * affiliation to a social security scheme exclusion criteria: * disability that does not allow the completion of questionnaires * acute intercurrent medical situation * use of electric wheelchair * under court protection.

Keywords: exercise disabled persons rehabilitation cross sectional studies social inclusion
assessment of efficacy of azd2281 in platinum sensitive relapsed serous ovarian cancer

Conditions: Ovarian Cancer

Summary: the primary purpose of this study to determine if azd2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy


Eligibility criteria:
inclusion criteria: * female patients with histologically diagnosed serous ovarian cancer or recurrent serous ovarian cancer. * patients must have completed at least 2 previous courses of platinum containing therapy; the patient must have been platinum sensitive to the penultimate chemo regimen. * for the last chemotherapy course prior to enrolment on the study, patients must have demonstrated an objective stable maintained response (partial or complete response) and this response needs to be maintained until completion of chemotherapy. * patients must be treated on the study within 8 wks of completion of their final dose of the platinum containing regimen. exclusion criteria: * previous treatment with parp inhibitors including azd2281 * patients with low grade ovarian carcinoma. * patients who have had drainage of their ascites during the final 2 cycles of their last chemotherapy regimen prior to enrolment on the study * patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).

Keywords: serous, ovarian cancer, parp, brca1, brca2, poly(adp ribose) polymerases, platinum sensitive, homologous recombination deficiency (hrd)
stability of short implants versus standard blx implants with internal sinus floor elevation in posterior maxilla

Conditions: Bone Resorption

Summary: implants in the maxillary posterior region are associated with compromised bone in both quantity - notably in vertical dimension- and quality. along with the fact that the posterior teeth are subjected to higher occlusal forces than the anterior teeth (marianne morand \& tassos irinakis, 2007). in order to overcome these shortcomings, various procedures have been advocated including open and closed sinus lift (nkenke e \& stelzle f, 2009; schropp et al, 2003). the use of short implants is a valid alternative for these procedures (wallace ss \& froum sj, 2003) sparing the need of applying augmentation techniques with the associated increased time, morbidity and complexity of such procedures.

to overcome anatomical and physiological limitations, different sinus augmentation techniques with immediate or delayed (6-8 months post augmentation) implant placement have been proposed. the most common one is the sinus elevation with a lateral window approach. although these protocols evoke a high level of success in augmenting the bone quantity (nkenke e \& stelzle f, 2009; schropp et al, 2003) many patients refuse them because of the invasiveness of the augmentative procedure, with obvious prolonged healing times and increased morbidity and costs (fugazzotto, 2003; bra¨gger et al, 2004; toffler, 2004). an alternative therapy for restoring areas of limited bone dimension is the placement of short implants (wallace ss \& froum sj, 2003). ''standard length implants'' are those of 10 mm in length and have been defined as the minimal length for anticipated success (griffin tj \& cheung ws, 2004).

Eligibility criteria:
inclusion criteria: * single edentuolous site at maxillary posterior region * the available bone height below the maxillary sinus should be 7-8mm * patients ≥ 20 years old * bucco-palatal bone width should be ≥6mm * adequate interarch space * bounded, single exclusion criteria: * patients with local pathological defects related to the area of interest. * patients with habits that may jeopardize the implant longevity and affect the results of the study such as alcoholism or parafunctional habits. * inadequate inter-arch space for implant prosthetic part * smokers * pregnancy
study of median lobe prostatic urolift procedure

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: the purpose of this study is to evaluate the safety and effectiveness of using urolift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (bph).

study objectives: evaluate the safety and effectiveness of the urolift® system when used in symptomatic benign prostatic hyperplasia (bph) subjects with an enlarged median lobe. study design: prospective, multicenter, non-blinded, single arm (non-randomized) study. sample size: a total of no more than 48 subjects will be enrolled. subject population: males age of 50 years or older diagnosed with lower urinary tract symptoms (luts) with enlarged median lobe.

Eligibility criteria:
inclusion criteria: * enlarged median lobe (ml) contributing to obstruction of the prostate * bph exclusion criteria: -
the role of n-acetyl-l-cysteine (nac) as an adjuvant to opioid treatment in patients with chronic neuropathic pain

Conditions: Neuropathic Pain

Summary: this study will test whether treatment with n-acetyl-l-cysteine (nac) is safe and decreases pain in patients with chronic neuropathic pain. the investigators hypothesize that nac will be a useful adjunct to opioid treatment in chronic neuropathic pain.

this is an open-label study to evaluate the safety and efficacy of n-acetyl-l-cysteine in patients with chronic neuropathic pain.

Eligibility criteria:
inclusion criteria: * 18-65 years old * non-cancer neuropathic pain * stable dose of opioids for pain * using breakthrough pain meds * still with persistent pain per vas exclusion criteria: * pregnant or nursing * serious medical or psychiatric illness (including uncontrolled hypertension) * active stomach ulcer, history or seizures or asthma * breakthrough pain meds other than opioids * using illicit drugs

Keywords: uncontrolled neuropathic pain
pre- vs post-pandemic risk-adjusted survival rates in the us hospitals

Conditions: In-hospital Mortality; Non-COVID Deaths; Surge

Summary: this study aims to perform a retrospective cohort study of administrative health data to understand how care delivery performance varies across us hospitals post-covid-19 pandemic compared to the pre-pandemic performance. we also hope to identify which factors contribute to performance changes.


Eligibility criteria:
the study cohort will include one random encounter per patient for all adult (age ≥18years) encounters. all inpatients with the premier healthcare database (pinc-ai) and those patients who were admitted under observation status and expired in the hospital or those who presented acutely to the emergency department and died in the emergency department will be considered as inpatients for the purpose of this study as per prior precedence in including such patients. all pediatric inpatients, skilled nursing facilities inpatients, long term acute care inpatients, rehabilitation facility inpatients, psychiatric inpatients, hospice inpatients, chemical dependency unit inpatients and deceased organ donor inpatients are excluded after applying encounter level exclusion criteria from this inpatient cohort. application of this encounter level exclusion will also preferentially exclude any children hospitals, skilled nursing facilities, acute long term care facilities, psychiatry hospitals, inpatient hospices and chemical dependency units.

Keywords: in-hospital mortality post pandemic hospital performance surge hospital recovery hospital performance
paroxetine safety and efficacy in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a systemic chronic auto-inflammatory disorder which imposes a remarkable burden of morbidity and mortality on global health. the complex interaction between genetics, environment, and immunological response contribute to ra pathogenesis. current treatment comprises conventional disease-modifying anti-rheumatic drugs (dmards) followed by biological dmards, if necessary, to achieve low disease activity or remission. therapeutics used in ra had limitations in tolerability, access, and response duration and magnitude. consequently, implementation of safe adjunctive treatment for ra is urgently needed to boost the therapeutic response.


Eligibility criteria:
inclusion criteria: * aged 23-57 years fulfilling 2010 american college of rheumatology - european league against rheumatism (acr-eular) classification criteria for ra (12) and had active inflammatory ra with no limit in disease duration. * patients received mtx, nonsteroidal anti-inflammatory drugs, selective cyclooxygenase-2 inhibitors, acetaminophen, and low dose of oral corticosteroids will be allowed to enroll the trial * intravenous, intra-articular or intramuscular corticosteroids; intra-articular hyaluronate sodium; biological dmards; and other dmards will not be permitted less than 4 weeks before the first dose of paroxetine. exclusion criteria: * patients refusing to give informed consent, diabetes, congestive heart failure, previous adverse reaction to paroxetine, oral prednisolone greater than 10 mg/day, receiving biological dmards, severe anemia, active infection, pregnancy or lactation, and clinically significant renal or hepatic disease.
every day counts: a lifestyle program for women with metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: this multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. the study will recruit 176 women with mbc in milwaukee (n=88) and chicago (n=88).

aims/objectives aim 1. to examine the efficacy of the every day counts intervention in producing significant post-intervention changes in multidimensional qol in women with mbc. hypothesis 1: women randomized to the immediate edc intervention (n=88) will exhibit greater improvements in multidimensional qol compared to women randomized to the attention control (n=88). aim 2. to investigate the mechanistic effects of the every day counts intervention on body composition, adipokines, serum biomarkers of inflammation and insulin sensitivity. hypothesis 2: the edc intervention leads to improved qol through mediating factors including body composition, prognostic serum biomarkers of inflammation and/or insulin resistance. exploratory aim 3: to explore if microrna (mirna) signatures associated with inflammation and/or metabolomics are altered with the edc intervention. hypothesis: mirnas identified in our pilot study (mir-10a-5p, mir-205-5p, and mir-211-5p) that regulate inflammation and/or metabolomics will be related to qol improvements and can identify women more likely to respond to lifestyle changes.

Eligibility criteria:
inclusion criteria: * adult (≥ 18 years), female * confirmed metastatic breast cancer * patients clinically stable with treated brain metastases are eligible * written documentation from their oncologist permitting study participation * determined to be "clinically stable" by their medical oncologist (i.e., no unintentional weight loss, no new symptoms or change in performance status for the past 4 weeks, no clinical \[including laboratory\] or radiologic evidence of disease progression, no recent or planned change in anti-neoplastic therapies, no reports of severe pain \[≥ grade 3 per the nci ctcae) * life expectancy \>6 months -written documentation from their oncologist permitting study participation * access to a mobile phone * understand/speak english fluently. * non-adherence to acs nutritional or pa guidelines for cancer survivors as documented by questionnaire. exclusion criteria: * does not meet the above criteria.
remote monitoring and contingency management reinforcement for alcohol abstinence

Conditions: Alcohol Use

Summary: this pilot project proposes to monitor real-world alcohol use using a novel technology-cell phone videorecordings in conjunction with breathalyzer recordings-and to conduct a small randomized study of this technology for reinforcing alcohol abstinence. individuals with frequent alcohol use (n = 30) will be asked to carry a study cell phone plus a handheld breathalyzer for one month. participants will be randomized to one of two conditions: alcohol monitoring or alcohol monitoring plus contingency management. in both conditions, research assistants will telephone participants on their cell phone an average of 10 times per week to request submission of a breathalyzer sample using the video monitoring function on the cell phone. samples will be time and date stamped, and the video containing the breathalyzer result will be sent to study staff via the cell phone. participants will be compensated for each video recorded within one hour of receiving the prompt. participants randomized to the contingency management condition will receive the same alcohol monitoring described above, and they will also receive reinforcement for each alcohol negative breath sample submitted within one hour of the prompt. data from this pilot project will be useful for (1) determining the feasibility of assessing alcohol use in the natural environment via breathalyzers and cell phone technology, and (2) estimating effect sizes of a cm intervention that reinforces alcohol abstinence using breathalyzers and cell phone technology. in an exploratory manner, we will also evaluate the reliability and validity of the video monitoring procedure and trends toward changes in psychosocial functioning.


Eligibility criteria:
inclusion criteria: * age \>21 years * frequent alcohol use * willing to use a cell phone and breathalyzer for 28 days * have a valid photo id (driver's license, passport, state id) * are willing to sign an off-campus property transfer form and return study equipment in four weeks exclusion criteria: * desire for, or have received, treatment for alcohol use in the past 6 months * non-english speaking
a study to assess the long-term efficacy and safety of axs-12 (reboxetine) in subjects with narcolepsy (encore)

Conditions: Narcolepsy; Cataplexy; Excessive Daytime Sleepiness

Summary: this study will evaluate the long-term efficacy and safety of axs-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (eds).

this study is a multi-center trial consisting of a 24-week open-label period, followed by a 4-week double-blind, placebo-controlled, randomized withdrawal period. at the week 24 visit, subjects will be randomized in a 1:1 ratio either to continue to receive axs-12 or to switch to placebo, for the next 4 weeks. eligible subjects will have previously participated in the axs-12-301 study.

Eligibility criteria:
inclusion criteria: * completed the treatment period of study axs-12-301 * willing and able to comply with the study requirements exclusion criteria: * significant change in medical history or concomitant medications since enrolling in the axs-12-301 study which, in the opinion of the investigator, would render the subject unsuitable to receive axs-12

Keywords: axs-12 narcolepsy cataplexy excessive daytime sleepiness reboxetine axsome
neoadjuvant electrochemotherapy for colorectal cancer - a randomized controlled trial

Conditions: Colorectal Cancer

Summary: this is a randomized controlled trial investigating efficacy of electrochemotherapy for early colorectal cancer

this is a phase 2 randomized controlled trial. the study is blinded. the aim of this study is to establish the safety and efficacy of treating patients with early colorectal cancer with electrochemotherapy, compared with electroporation alone, as a down staging and immune-response enhancing treatment prior to intended curative surgery. the study involves recruitment of patients with histologically verified rectal and sigmoid colon cancer with no indication for neoadjuvant chemoradiotherapy (experimental or standard care based) prior to intended curative surgery. in total the study will involve 24 patients, of these, 12 patients are treated with electrochemotherapy (bleomycin) and 12 patients with electroporation alone (placebo) in relation to the intervention, clinical examination, blood samples, biopsies and questionnaires will be collected to evaluate safety, tumor respons and immunologic response to the treatment. patients will be followed for one month after the elective surgery.

Eligibility criteria:
inclusion criteria: * patients must be mentally capable of understanding the information given. * patients must give written informed consent. * endoscopically suspected or histologically verified malignant tumor of the rectum or sigmoid colon. * tumor described as passable at index endoscopy. * men or women aged at least 18 years. * case reviewed by mdt (surgery, radiology, oncology). case considered curable with standard surgical resection. * asa class i-ii (classification of the american society of anesthesiology) exclusion criteria: * indication for neoadjuvant chemoradiation or chemotherapy prior to surgery * uncorrectable coagulation disorder. * patients with icd or pacemaker units. * ongoing immunosuppressive treatment. * patients with concomitant use of phenytoin. * myocardial insufficiency, defined as nyha class \>2 * concurrent treatment with an investigational medicinal product. * patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments. * advanced tumor stages, clinical uicc stage iv. * acute surgical resection. * pregnancy * medical history of severe pulmonary disease. * previous cumulative dose of bleomycin exceeding 250mg/m2. * bmi \> 35 * renal impairment, defined as egfr \<40 ml/min
study of speech function in epileptic patients based on stereoelectroencephalography signal

Conditions: Epilepsy

Summary: based on stereoelectroencephalography model in the treatment of epilepsy patients, this study conducted language-related experimental studies without interfering with normal monitoring treatment. meanwhile, voice data and intracranial electrophysiological data were collected for analysis. to study the mechanism related to the language function of patients, try to establish a model to decode the intracranial electrophysiological data related to language.


Eligibility criteria:
inclusion criteria: * patients with focal refractory epilepsy also need preoperative evaluation with seeg exclusion criteria: * history of major depression or psychiatric disorders and medication that causes symptoms of psychiatric disorders * patients with severe cognitive impairment (mmse score ≤15), unable to complete the language function test

Keywords: epilepsy stereoelectroencephalography speech
lsh silicone hydrogel soft hydrophilic contact lens for daily wear

Conditions: Myopia

Summary: this study is to evaluate the performance of the lsh (mangofilcon a) silicone hydrogel soft contact lenses when used as a daily wear contact lens for the correction of myopia.


Eligibility criteria:
inclusion criteria: * have been advised that the contact lenses they will be wearing for the next 3 months are being used for investigational purposes and that their informed consent will be needed and documented prior to the start of the study. * visual acuity must be correctable to 20/30, with spherical lenses ranging in power from -1.00 to -5.00d, astigmatism≤1.50d. * have been successfully wearing soft (hydrophilic) contact lenses for at least one month prior to entering the study. (success means both subject and practitioner are satisfied with visual acuity, comfort, and ocular physiology). * have non-diseased eyes which are normal or which have no preexisting ocular condition which would interfere with the patient's ability to adapt to the new pair of lsh silicone hydrogel soft (hydrophilic) contact lenses. a normal eye is defined as one having all the following characteristics: 1. no evidence of lid infection. 2. no structural lid abnormality. 3. no conjunctival abnormality or infection. 4. a cornea which is clear with no edema, staining, vascularization or abnormal opacities, all as observed by slit lamp examination. 5. no iritis. 6. no other active ocular disease that would contraindicate use of the investigational lens. 7. no gpc (giant papillary conjunctivitis, tarsal abnormality) grade 2 or greater * use no ocular medication. * have no known sensitivity to solutions currently used for contact lens care. * have binocular correction with contact lenses. exclusion criteria * astigmatism \>1.50d * no monocular or monovision fits may be included. * pregnant and lactating women are excluded from the study * minors (under age 18) are excluded from the study
effect of biphasic insulin aspart 50 on blood glucose control in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months * hba1c (glycosylated haemoglobin a1c) between 7.5% - 12.0% (both inclusive) * fpg (fasting plasma glucose) higher than 7.0 mmol/l * bmi (body mass index) 23-40 kg/sq.m (both inclusive) exclusion criteria: * metformin contraindications according to local practice * systemic use of tzds (thiazolidinediones) for more than 1 month within 6 months prior to this trial
a clinical prospective observational study of near infrared spectroscopy to detect subcranial hematoma

Conditions: Intracranial Hemorrhages

Summary: this trial is a clinical prospective observational study. cases meeting the entry criteria undergo near-infrared spectroscopy(nirs）detection. data collection mainly includes hematoma thickness on cranial ct, and bilateral nirs data.this trial tries to explore the reliability and accuracy of nirs detection of subcranial hematoma.


Eligibility criteria:
inclusion criteria: 1. age above 18 years old 2. unilateral subcranial hemorrhage confirmed by cranial ct exclusion criteria: 1. bilateral subcranial hemorrhage 2. intracranial pneumoperitoneum in the location of the hemorrhage on cranial ct 3. obvious skull fracture in the location of hemorrhage on cranial ct